<DOC>
	<DOCNO>NCT00006458</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody therapy treat patient relapsed refractory non-small cell lung cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Relapsed Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose-limiting toxicity maximum tolerate dose yttrium Y 90 anti-CEA monoclonal antibody MN-14 patient relapse refractory non-small cell lung cancer . II . Determine dosimetric pharmacokinetic property treatment regimen blood , normal organ , tumor patient . III . Determine stability complexation circulate carcinoembryonic antigen radioantibody plasma patient . IV . Determine antibody response patient treatment regimen . V. Determine antitumor effect treatment regimen patient . OUTLINE : This dose escalation study yttrium Y 90 anti-CEA monoclonal antibody MN-14 ( 90Y-hMN-14 ) . Patients undergo pretherapy image indium In 111 anti-CEA monoclonal antibody MN-14 IV 30-40 minute day -7 -6 , follow external scintigraphy day -7 -6 0 . Patients show positive localization least one documented tumor site receive 90Y-hMN-14 IV 30-40 minute day 0 . Cohorts 3-6 patient receive escalate dos 90Y-hMN-14 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow 2 , 4 , 8 , 12 week ; every 3 month 2 year ; every 6 month 3 year . PROJECTED ACCRUAL : A total 15-30 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Adenocarcinoma , squamous large cell , mixed cell histology Patients nonadenocarcinomatous disease must evidence carcinoembryonic antigen ( CEA ) production expression document one following : Serum CEA least 10 ng/mL Positive immunohistology either primary tumor metastasis CEAspecific monoclonal antibody Must receive least one prior regimen standard chemotherapy , indicate , great 6,900 cGy thoracic radiotherapy Patients stage IIIA/B unresectable disease receive prior radiotherapy must show evidence progressive disease ( great 25 % increase primary tumor appearance new lesion ) Patients stage IIIB IV disease receive prior radiotherapy primary index lesion must show evidence stable progressive disease CT scan least 4 week apart Less 25 % tumor involvement bone marrow No known , active brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL AST great 2 time upper limit normal ( ULN ) No hepatitis B C No serious liver abnormality Renal : Creatinine great 1.5 time ULN No urinary incontinence Cardiovascular : Ejection fraction least 50 % MUGA Pulmonary : FEV1 least 60 % DLCO least 50 % Other : No severe anorexia , nausea , vomit No significant medical problem No prisoner No reactivity humanize MN14 ( patient prior exposure chimeric humanize antibody ) HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior stem cell transplantation highdose chemotherapy No concurrent growth factor Chemotherapy : See Disease Characteristics See Biologic At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Prior radiotherapy le 30 % red marrow allow Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>